Zyvox Safety Alert Undercuts PhRMA Good News Events
This article was originally published in RPM Report
Executive Summary
Talk about bad timing. A March 16 safety alert issued by the Food & Drug Administration regarding Pfizer Inc.'s antibiotic linezolid (Zyvox) couldn't have come at a worse time. If there was any doubt left on the point, it is gone now: drug safety will be the dominant theme for the pharmaceutical industry in 2007.
You may also be interested in...
The Agency that Cries Wolf
FDA is being more proactive about issuing safety warnings. But, as GSK's experience with Advair shows, what looks like bad news to Wall Street may not matter as much to physicians. FDA is well aware of the limitations of its risk communication techniques, but for now the agency is commited to transparency.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.